HHS Action Plan to Prevent Healthcare-Associated Infections: AppendicesAppendix A Metric Number and Label | Metric | Measurement System | National 5-Year Prevention Target | 1. CLABSI 1 | CLABSIs per 1,000 device days by ICU and other locations | NHSN Administrative discharge data1 | CLABSIs per 1,000 device days by ICU and other locations below present NHSN 25th percentile by location type (75% reduction in SIR) | 2. CLABSI 2 | Laboratory detected bacteremia per 1,000 patient days | ADT/lab System Data Streams | 50% reduction in laboratory detected bacteremia per 1,000 patient days | 3. CLABSI 3 | CLABSIs per 100 patient months | NHSN Administrative discharge data | 50% reduction in CLABSIs per 100 patient months | 4. CLABSI 4 | Central line bundle compliance (non-emergent insertions) | NHSN CLIP module | 100% compliance with central line bundle (non-emergent insertions) | 5. C diff 1 | Case rate per patient days and administrative/discharge data for ICD9 coded Clostridium difficile Infections | NHSN MDRO module and Administrative discharge data | 30% reduction in the case rate per patient days and administrative / discharge data for ICD9 coded Clostridium difficile Infections NOTE: Preventability of endemic CDI is unknown; therefore, the experts suggested that HHS revisit this target in 2 years as prevention research findings may become available | 6. C diff 2 | Contact precautions | NHSN MDRO module | 100% compliance with contact precautions | 7. C diff 3 | Appropriate hand hygiene practices | NHSN MDRO module | 100% compliance with appropriate hand hygiene practices | 8. CAUTI 1 | Rate of BSI secondary to UTI / 1,000 patient days | NHSN | 50-75% reduction in the rate of BSI secondary to UTI / 1,000 patient days | 9. CAUTI 2 | # of symptomatic UTI / 1,000 urinary catheter days [Number of UTIs (ICD9+not present on admission) / (# major surgery ICD9+ urinary catheter ICD9)]*100 discharges | NHSN Administrative discharge data | 25% reduction in the number of symptomatic UTI / 1,000 urinary catheter days 25% reduction in the [Number of UTIs (ICD9+not present on admission) / (# major surgery ICD9+ urinary catheter ICD9)]*100 discharges2 | 10. CAUTI 3 | (Urinary catheter days / patient days)*100 | NHSN | 50% reduction in (urinary catheter days / patient days)*100 | 11. MRSA 1 | Incidence rate (number per 100,000 persons) of invasive MRSA infections | CDC EIP/ABCs | 50% reduction in incidence rate of all healthcare-associated invasive MRSA infections | 12. MRSA 2 | Incidence rate (number per 1,000 patient days) of hospital-onset MRSA bacteremia (hospital wide) | NHSN (starting 2009) | 50% reduction in incidence rate of hospital-onset MRSA bacteremia (hospital wide) | 13. MRSA 3 | Number of hospitalizations with non-present on admission MRSA bacteremia/pneumonia/sepsis Number of hospitalizations with non-present on admission MRSA not otherwise specified (NOS)/pneumonia/sepsis | NHDS Administrative discharge data | 25% reduction in hospitalizations with non-present on admission MRSA not otherwise specified (NOS)/pneumonia/sepsis 90% of facilities with fewer “hospitalizations” with non-present on admission MRSA not otherwise specified (NOS)/pneumonia/sepsis than predicted (i.e. model prediction) | 14. SSI 1 | Deep incision and organ space infection rates using NHSN definitions (SCIP procedures) | NHSN | Median deep incision and organ space infection rate for each procedure/risk group will be at or below the current NHSN 25th percentile | 15. SSI 2 | Adherence to SCIP/NQF infection process measures (perioperative antibiotics, hair removal, postoperative glucose control, normothermia) | CMS SCIP | 95% adherence rates to each SCIP/NQF infection process measure | 16. VAP 1 | VAP rate, ventilator utilization (vent days), intermediate outcome – duration of ventilation | NHSN definitions | Track performance, no national target | 17. VAP 2 | VAP process bundle: Continuous assessment of head of bed elevation; Daily oral care and daily assessment of readiness to extubate and sedation levels | Direct local observation | 100% compliance with each metric in the VAP process bundle within 2 years |
Appendix B Metric Number and Label | Metric | Measurement System | National 5-Year Prevention Target | NQF Measures3 | Compendium Measures4 | 1. CLABSI 1 | CLABSIs per 1000 device days by ICU and other locations | CDC NHSN; Administrative discharge data5 | CLABSIs per 1000 device days by ICU and other locations below present NHSN 25th percentile by location type (75% reduction in SIR) | CLABSI rate: CLABSI rate for ICU and high-risk nursery (NRN) patients | CLABSI rate | 2. CLABSI 4 | Central line bundle compliance (non-emergent insertions) | NHSN CLIP Module | 100% compliance with central line bundle (non-emergent insertions) | Central line bundle compliance (hand hygiene; maximal barrier precautions upon insertion; Chlorhexidine skin antisepsis; Optimal catheter site selection; Daily review of line necessity with prompt removal of unnecessary lines.) | 1. Compliance with CVC insertion guidelines as documented on an insertion checklist 2. Compliance with documentation of daily assessment regarding the need for continuing CVC access. 3. Compliance with cleaning of catheter hubs and injection ports before they are accessed. 4. Compliance with avoiding the femoral vein site for CVC insertion in adult patients. | 3. C diff 1 | Case rate per patient days; administrative/discharge data for ICD9 coded Clostridium difficile Infections | CDC NHSN MDRO module; Administrative discharge data | 30% reduction in the case rate per patient days and administrative/discharge data for ICD9 coded Clostridium difficile Infections. NOTE: Preventability of endemic CDI is unknown; therefore, meeting attendee experts suggested that HHS revisit this target in 2 years as prevention research findings may become available. | | CDI rates should be calculated according to the recently published recommendations. (Rates for healthcare onset, healthcare facility associated; community onset, healthcare facility associated; community associated; indeterminate onset; unknown; and recurrent CDIs) | 4. CAUTI 2 | # of symptomatic UTI / 1000 urinary catheter days [Number of UTIs (ICD9+not present on admission) / (# major surgery ICD9+ urinary catheter ICD9)]*100 discharges | CDC NHSN Administrative Discharge data | 25% reduction in the number of symptomatic UTI/1000 urinary catheter days 25% reduction in the [Number of UTIs (ICD9+not present on admission) / (# major surgery ICD9+urinary catheter ICD9)]*100 discharges6 | Catheter-associated urinary tract infection rate for intensive care unit patients. | Rates of symptomatic CAUTI, stratified by risk factors (age, sex, ward, indication, and catheter-days) | 5. MRSA 1 | Incidence rate (number per 100,000 persons) of invasive MRSA infections | CDC EIP/ABCs | 50% reduction in incidence rate of all healthcare-associated invasive MRSA infections | | Overall prevalence or prevalence density of MRSA colonization and/or infection | 6. SSI 1 | Deep incision and organ space infection rates using NHSN definitions (SCIP procedures) | CDC NHSN | Median deep incision and organ space infection rate for each procedure/risk group will be at or below the current NHSN 25th percentile | Surgical site infection rate: Deep wound and organ space infections as a result of elective surgery to include coronary artery bypass graft (CABG) and cardiac surgery; hip or knee arthroplasty; colon surgery; hysterectomy (abdominal and vaginal); and vascular surgery. | Surgical site infection rate | 7. SSI 2 | Adherence to SCIP/NQF infection process measures (perioperative antibiotics, hair removal, postoperative glucose control, normothermia) | CMS SCIP | 95% adherence rates to each SCIP/NQF infection process measure. | Cardiac surgery patients with controlled postoperative serum glucose; Surgery patients with appropriate hair removal; Prophylactic antibiotics received; Prophylactic antibiotics selection; Prophylactic antibiotics discontinued | Compliance with Centers for Medicare and Medicaid Services antimicrobial prophylaxis guidelines. |
Appendix C – Current HHS HAI-Related Research Responsibilities (AHRQ, CDC, CMS, and NIH) | AHRQ | CDC | CMS | NIH | Basic Discovery | | Biofilms, resistance mechanisms | | Vaccines, biofilms, studies of pathogenesis (intramural and extramural) | Surveillance | At a population level, using hospital inpatient and outpatient administrative databases | National Healthcare Safety Network (NHSN), Active Bacterial Core Surveillance, new measure development and validation, e-surveillance, electronic medical record capture | | Electronic healthcare epidemiology surveillance system currently being installed at the NIH/Clinical Center | Epidemiology | Population-based epidemiologic studies (longitudinal trends, population risk associations) | Outbreak response, molecular epidemiology, other epidemiologic studies (burden estimates, risk factors, etc.) | | Intramural studies in a unique clinical research hospital setting | Etiology | | Identification of emerging pathogens through surveillance and outbreak response | | Funding for clinical studies, basic studies characterizing new and/or emerging pathogens | Prevention Efficacy/Effectiveness | | Prevention demonstration projects, intervention studies, investigation of novel/ innovative prevention strategies | | Proof of principle studies (intramural), comparative trials (extramural) | Prevention Implementation | Within organizations, systems of care, institutions, primary care networks | Prevention demonstration projects, prevention collaboratives, behavioral epidemiology, education, promotion | Through quality reporting, payment incentives, and special Quality Improvement Organization (QIO) programs | Clinical studies, including comparative trials (intramural and extramural) | Guidelines | Generate the evidence base for further guideline development | Healthcare Infection Control Practices Advisory Committee (HICPAC) produces evidence-based guidelines and related guidance; Maintain consistent case definitions in guidelines and NHSN | | Research contributions to inform Public Health Service guidelines, society-sponsored guidelines, etc. | Treatment Comparative Effectiveness Implementation | Comparative effectiveness of treatments Within organizations, systems of care, institutions, primary care networks | Comparative effectiveness of prevention strategies | Comparative effectiveness through information from coverage with evidence development | Comparative trials (intramural and extramural) | Quality/Safety of Healthcare | Patient Safety Organizations, measurement tools for baseline and evaluation and quality improvement, training, data collection | NHSN as a system to track infections; Develop baseline through measurement, training, and data collection; NHSN as a quality improvement tool | Through quality reporting, payment incentives, and special QIO programs | Developed and implemented electronic occurrence reporting system and ongoing clinical quality/performance measurement/performance improvement program at the NIH/Clinical Center | Efficiency and Costs | Improved quality and reduced costs, avoidable admissions and re-admissions (HAIs) | Cost estimate studies, assess impact, assess unintended consequences of prevention initiatives and policies related to HAI prevention | CMS does not pay for certain hospital-acquired infections | |
Appendix D Top 5 Hospital Allegations for Complaints & Incidents, CY2005 to CY2008 | TOP 5 HOSPITAL ALLEGATIONS FOR COMPLAINTS & INCIDENTS | | | | Ranking | Allegation | # Allegations | | | | | CY2008 to date (01012008-08182008) | | | | 1 | Quality of Care/Treatment | 2426 | 2 | Restrain/Seclusion - Death | 2074 | 3 | Resident/Patient/Client Rights | 1205 | 4 | Nursing Services | 832 | 5 | EMTALA | 826 | | | | 13 | Infection Control | 216 | | | | | | | | CFY2007 | | | | | 1 | Quality of Care/Treatment | 4103 | 2 | Resident/Patient/Client Rights | 2225 | 3 | EMTALA | 1346 | 4 | Nursing Services | 1157 | 5 | Resident/Patient/Client Abuse | 631 | | | | 11 | Infection Control | 405 | | | | | | | | CY2006 | | | | | 1 | Quality of Care/Treatment | 3677 | 2 | Resident/Patient/Client Rights | 2101 | 3 | EMTALA | 1517 | 4 | Nursing Services | 1105 | 5 | Resident/Patient/Client Abuse | 608 | | | | 12 | Infection Control | 314 | | | | | | | | CY2005 | | | | | 1 | Quality of Care/Treatment | 3872 | 2 | Resident/Patient/Client Rights | 3240 | 3 | EMTALA | 1483 | 4 | Nursing Services | 1139 | 5 | Resident/Patient/Client Neglect | 705 | | | | 12 | Infection Control | 384 | | | | | | | Source: QIES Workbench 8/21/2008; ACTS; Pennsylvania | Complaints and incidents are combined for this report | Note: Includes data for the State of Pennsylvania |
Appendix E Hospital Acquired Conditions, Including Codes, Selected for October 1, 2008
HAC | CC/MCC (ICD-9-CM Codes) | 1. Foreign Object Retained After Surgery | 998.4 (CC) 998.7 (CC) | 2. Air Embolism | 999.1 (MCC) | 3. Blood Incompatibility | 999.6 (CC) | 4. Pressure Ulcer Stages III & IV | 707.23 (MCC) 707.24 (MCC) | 5. Falls and Trauma: - Fracture - Dislocation - Intracranial Injury - Crushing Injury - Burn - Electric Shock | Codes within these ranges on the CC/MCC list: 800-829 830-839 850-854 925-929 940-949 991-994 | 6. Catheter-Associated Urinary Tract Infection (UTI) | 996.64 (CC) Also excludes the following from acting as a CC/MCC: 112.2 (CC) 590.10 (CC) 590.11 (MCC) 590.2 (MCC) 590.3 (CC) 590.80 (CC) 590.81 (CC) 595.0 (CC) 597.0 (CC) 599.0 (CC) | 7. Vascular Catheter-Associated Infection | 999.31 (CC) | 8. Manifestations of Poor Glycemic Control | 250.10-250.13 (MCC) 250.20-250.23 (MCC) 251.0 (CC) 249.10-249.11 (MCC) 249.20-249.21 (MCC) | 9a. Surgical Site Infection, Mediastinitis Following Coronary Artery Bypass Graft (CABG) | 519.2 (MCC) And one of the following procedure codes: 36.10–36.19 | 9b. Surgical Site Infection Following Certain Orthopedic Procedures | 996.67 (CC) 998.59 (CC) And one of the following procedure codes: 81.01-81.08, 81.23-81.24, 81.31-81.38, 81.83, 81.85 | 9c. Surgical Site Infection Following Bariatric Surgery for Obesity | Principal Diagnosis – 278.01 998.59 (CC) And one of the following procedure codes: 44.38, 44.39, or 44.95 | 10. Deep Vein Thrombosis and Pulmonary Embolism Following Certain Orthopedic Procedures | 415.11 (MCC) 415.19 (MCC) 453.40-453.42 (MCC) And one of the following procedure codes: 00.85-00.87, 81.51-81.52, or 81.54 |
Appendix F Hospital Compare Measures as of October 1, 2008 Acute Myocardial Infarction (AMI) – Heart Attack | Aspirin at Arrival | Aspirin Prescribed at Discharge | ACE Inhibitor or Angiotensin Receptor Blocker (ARB) for Left Ventricular Systolic Dysfunction | Adult Smoking Cessation Advice/Counseling | Beta-Blocker Prescribed at Discharge | Beta-Blocker at Arrival | Fibrinolytic Therapy Received within 30 Minutes of Hospital Arrival | Primary Percutaneous Coronary Intervention (PCI) within 90 Minutes of Hospital Arrival | AMI 30-day Mortality | Heart Failure (HF) | Discharge Instructions | Evaluation of Left Ventricular Systolic Function | ACE Inhibitor or Angiotensin Receptor Blocker (ARB) for Left Ventricular Systolic Dysfunction | Adult Smoking Cessation Advice/Counseling | HF 30-day Mortality | Pneumonia (PN) | Oxygenation Assessment | Pneumococcal Vaccination | Blood Culture Performed in the Emergency | Department Prior to Initial Antibiotic Received in the Hospital | Adult Smoking Cessation Advice/Counseling | Initial Antibiotic Received within 6 Hours of Hospital Arrival | Appropriate Initial Antibiotic Selection | Influenza Vaccination | PN 30-day Mortality | Surgical Care Improvement Project (SCIP) | Prophylactic Antibiotic Received One Hour Prior to Surgical Incision | Prophylactic Antibiotic Selection for Surgical Patients | Prophylactic Antibiotics Discontinued within 24 Hours After Surgery End Time | Surgery Patients with Recommended Venous Thromboembolism (VTE) Prophylaxis Ordered | Surgery Patients Who Received Recommended Venous Thromboembolism (VTE) Prophylaxis Within 24 Hours Prior to Surgery to 24 Hours After Surgery | Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) | Communication with nurses | Communication with doctors | Responsiveness of hospital staff | Pain management | Communication about medicines | Discharge information | Cleanliness of hospital environment | Quietness of hospital environment | Overall rating of hospital | Willingness to recommend hospital | Children’s Asthma Care | Use of relievers for inpatient asthma | Use of systemic corticosteroids for inpatient asthma |
1 Any source that would provide nationally representative hospital discharge coding (i.e., ICD9 or, in the future, ICD10) data, including such sources as the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project, the CDC National Center for Health Statistics or National Hospital Discharge Survey, and those in the Centers for Medicare and Medicaid Services (CMS). 2 Zhan C, et.al. Medical Care (in press) 5 Any source that would provide nationally representative hospital discharge coding (i.e., ICD9 or, in the future, ICD10) data, including such sources as the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project, the CDC National Center for Health Statistics or National Hospital Discharge Survey, and those in the Centers for Medicare and Medicaid Services (CMS). 6 Zhan C, et.al. Medical Care (in press)
|